Literature DB >> 7875658

Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice.

S N Huang1, F V Chisari.   

Abstract

Hepatocyte turnover rates were studied in two lineages of transgenic mice that overproduce the hepatitis B virus (HBV) large envelope protein and retain filamentous hepatitis B surface antigen (HBsAg) particles in the endoplasmic reticulum, resulting in the formation of ground glass hepatocytes. The high producer lineage (50-4) develops a necroinflammatory liver disease that progresses to hepatocellular carcinoma (HCC), whereas the low producer lineage (107-5) displays no histopathologic changes other than ground glass hepatocytes. Bromodeoxyuridine (BrdU)-labeling studies of S-phase hepatocytes provide quantitative evidence for a strong, sustained proliferative response in the hepatocytes in lineage 50-4 that occurs after the onset of hepatocellular injury but long before the development of liver cell tumors. In contrast, the level of hepatocellular proliferation in lineage 107-5 is the same as nontransgenic controls. The findings support the concept that sustained hepatocellular proliferation plays an important role in the development of hepatocellular carcinoma (HCC).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875658

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

2.  The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice.

Authors:  C Trierweiler; B Hockenjos; K Zatloukal; R Thimme; H E Blum; E F Wagner; P Hasselblatt
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

3.  Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.

Authors:  J Petersen; M Dandri; A Bürkle; L Zhang; C E Rogler
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice.

Authors:  Xiao-Zhen Kang; Xue-Ran Guo; Bin-Bing Chen; Tian-Ying Zhang; Quan Yuan; Pei-Jer Chen; Jun Zhang; Ning-Shao Xia
Journal:  Hum Vaccin Immunother       Date:  2018-04-12       Impact factor: 3.452

5.  Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis.

Authors:  Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Sang Gyun Kim; Young Koog Cheon; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Joon Seong Lee; So-Young Jin; Chan Sup Shim; Boo Sung Kim
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

Review 6.  Pathogenesis of hepatitis B virus infection.

Authors:  F V Chisari; M Isogawa; S F Wieland
Journal:  Pathol Biol (Paris)       Date:  2010-02-08

7.  Hepatitis B virus replication is cell cycle independent during liver regeneration in transgenic mice.

Authors:  L G Guidotti; B Matzke; F V Chisari
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Comparison of intrahepatic lymphocytes from normal and growth hormone transgenic mice with chronic hepatitis and liver cancer.

Authors:  C L Hardy; P S Bhathal; K J Snibson; T E Adams
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

9.  Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.

Authors:  M Borzio; D Trerè; F Borzio; A R Ferrari; S Bruno; M Roncalli; G Colloredo; G Leandro; F Oliveri; M Derenzini
Journal:  Mol Pathol       Date:  1998-04

10.  Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress.

Authors:  Hui-Ching Wang; Han-Chieh Wu; Chien-Fu Chen; Nelson Fausto; Huan-Yao Lei; Ih-Jen Su
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.